Elan due to conclude strategic review

DUBLIN and Athlone- based pharmaceutical company Elan is hoping to conclude its ongoing strategic review in the near term, its chief executive said yesterday.

Speaking from a healthcare conference, hosted by investment bank Goldman Sachs, in New York, Kelly Martin said that “a lot of people are interested in talking to us”, adding that the company’s management expects some outcome “in the near term.”

Mr Martin added – via a webcast from the Elan website – that the company is still confident of selling its drug delivery business EDT (Elan Drug Technologies) when markets pick up.